They found that their novel therapeutics responded in a dose-dependent decrease in the androgen receptor variants. In addition there was additive toxicity with combined therapeutics. They were able to demonstrate a reduction in the downstream transcriptional activity for ARv7 and ARFL. So overall they were able to successfully decrease the stability of the androgen receptor variants with the added combinations only increasing the in vivo response. This work represents a potential significant contribution to the furthering the treatment of castrate resistant prostate cancer.
Presented By: Joseph A. Baiocco
Written By: Janet Baack Kukreja (@janetkukreja), MD, MPH, Urologic Oncology Fellow, Department of Urology, UT MD Anderson Cancer Center, Houston, TX, Ashish M. Kamat, MD, MBBS, FACS, Wayne B. Duddlesten Professor, Department of Urology, UT MD Anderson Cancer Center, Houston TX
at the 2017 AUA Annual Meeting – May 12 – 16, 2017 – Boston, Massachusetts, USA